Oraya Therapeutics's Successful INTREPID Study Outcomes Presented at EURETINA 2012 Congress  
9/21/2012 9:40:33 AM

NEWARK, Calif.--(BUSINESS WIRE)--Oraya Therapeutics, Inc. today announced that the results of the INTREPID trial of radiation therapy for wet AMD were first presented during the 12th EURETINA Congress in Milan, Italy. The INTREPID study is the first sham-controlled double-masked trial to evaluate the effectiveness and safety of a one-time radiation therapy in conjunction with as-needed anti-VEGF injections for the treatment of wet AMD. A total of 21 sites in five European countries participated in the trial with a total enrollment of 230 subjects.